CERo Therapeutics Holdings, Inc. (CERO)

OTCMKTS · Delayed Price · Currency is USD
0.0340
-0.0005 (-1.45%)
At close: Mar 13, 2026
Market Cap1.10M -77.4%
Revenue (ttm)n/a
Net Income-49.19M
EPS-98.71
Shares Out32.41M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume427,342
Average Volume665,869
Open0.0350
Previous Close0.0345
Day's Range0.0340 - 0.0357
52-Week Range0.0330 - 28.4000
Beta0.32
RSI30.97
Earnings DateMar 23, 2026

About CERO

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol CERO
Full Company Profile

Financial Performance

Financial Statements